-
June 12, 2021
Tumor Biology Matters Bookmark
Lola Rahib, PhDArticle from Let’s Win! Pancreatic Cancer: Results from the Know Your Tumor program shows overall survival benefit for patients with an actionable alteration and who received a matched therapy, compared to those with an actionable alteration and who did not receive a matched therapy.
.
-
April 28, 2021
How Can Detection of Tumor DNA in the Blood Aid Advanced Cancer Treatment?
With:As a tumor grows, it may shed fragments of its DNA into the patient’s bloodstream. After treatment, if part of the tumor remains or it begins to grow again, more of this circulating tumor DNA (ctDNA) may enter the blood. That raises the possibility that detecting ctDNA could help clinicians monitor molecular or minimal residual disease—cancer that remains after treatment and cannot be detected… Read more »
-
January 29, 2021
Targeted Therapy for Hepatocellular Carcinoma Bookmark
George Lundberg, MDThis scientific review paper published in the journal Signal Transduction and Targeted Therapy discusses recent research into newer medications that show promise as targeted therapies for some cases of primary hepatocellular carcinoma, following molecular testing.
.
-
December 3, 2020
Léon C. van Kempen, PhD, on a Successful Molecular Tumor Board in NSCLC Bookmark
George Lundberg, MDThis article from MedPage Today discusses recent study findings demonstrating that patients with complex cases of non-small cell lung cancer can benefit from the insights of a molecular tumor board.
.
-
October 16, 2020
Molecular Profiling in Metastatic Colorectal Cancer Bookmark
George Lundberg, MDArticle from the academic journal Oncology, curated by Contributing Editor George Lundberg, MD, who notes:
Molecular testing is essential to guide effective treatment in metastatic colorectal cancer. This academic review article provides a good overview of the topic.
.
-
August 15, 2020
FDA OKs Liquid Biopsy to Identify EGFR-Positive Lung Cancer Bookmark
George Lundberg, MDArticle from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes:
The U.S. Food and Drug Administration (FDA) has approved a liquid biopsy test (a type of biopsy that uses a blood draw instead of surgery) for detecting whether patients have EGFR mutations in their metastatic lung tumors, which could help guide treatment options.
Go to full article published by MedPage Today.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 15, 2020
Pembrolizumab Provides Long-Term Benefit in Melanoma, Regardless of BRAF+ Status or Prior Targeted Therapy Bookmark
George Lundberg, MDArticle from OncLive curated by Editor in Chief George Lundberg, MD, who notes:
A new study shows that the drug pembrolizomab significantly prolongs survival in patients with metastatic melanoma, regardless of whether their tumors have mutations in the BRAF gene or if they’ve had prior treatment with targeted therapy.
Go to full article published by OncLive.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 7, 2020
The Central Nervous System Tumor Methylation Classifier Changes Neuro-Oncology Practice for Challenging Brain Tumor Diagnoses and Directly Impacts Patient Care Bookmark
George Lundberg, MDAcademic research paper from Clinical Epigenetics curated by Editor in Chief George Lundberg, MD, who notes:
Brain tumor treatment decisions may be improved by integrating methylation-based tumor classification into the diagnosis process. Methylation refers to specific chemical features of tumor DNA that may impact how well different treatments might work.
Go to full academic research paper from Clinical Epigenetics.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 7, 2020
Brain Tumor Liquid Biopsy Detects DNA Methylation Profiles Bookmark
George Lundberg, MDArticle from Clinical OMICs curated by Editor in Chief George Lundberg, MD, who notes:
Researchers have recently demonstrated a noninvasive way to diagnose and classify brain tumors using a blood test. This promising “liquid biopsy” method detects cell-free tumor DNA in the blood and analyzes its chemical features—specifically, its “methylation patterns”—with high sensitivity and accuracy. Such a test could help guide treatment decisions.
Go to full article published by Clinical OMICs.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
July 11, 2020
Adult H3K27M-Mutant Diffuse Midline Glioma with Gliomatosis Cerebri Growth Pattern: Case Report and Review of the Literature Bookmark
George Lundberg, MDResearch paper from the International Journal of Surgery Case Reports curated by Editor in Chief George Lundberg, MD, who notes:
We present here an open-access case report and literature review of a patient with the H2K27M-mutant variant of diffuse midline glioma.
Go to full paper published in the International Journal of Surgery Case Reports.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.